Cytokinetics (CYTK) said Friday the US Food and Drug Administration's cardiovascular and renal drugs advisory committee will meet on Dec. 13 to review its...
Robert I Blum, Director, President & CEO, on June 15, 2022, sold 10,000 shares in Cytokinetics (CYTK) for $394,000. Following the Form 4 filing with the...
Cytokinetics (CYTK) said Friday the US Food and Drug Administration has extended the Prescription Drug User Fee Act date for the company's new drug...
Cytokinetics (CYTK) said Thursday it has started an open-label extension clinical study to assess the long-term safety and tolerability of reldesemtiv in...
| Address | 350 Oyster Point Boulevard South San Francisco, California 94080 |
| Phone | +1.650.624.3000 |
| Number of Employees | 130 |
| Recent SEC Filing | 06/24/2022 8-K |
| President, Chief Executive Officer & Director | Robert I. Blum |
| Vice President-Development Operations | Eric Terhaerdt |
| Chief Financial Officer & Senior Vice President | Ching W. Jaw |
| Executive Vice President-Research & Development | Fady Ibraham Malik |
| Price Open | $47.51 |
| Previous Close | $47.25 |
| 52 Week Range | $17.72 - 48.31 |
| Market Capitalization | $4.0 B |
| Shares Outstanding | 85.7 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 08/04/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$3.20 |
| Beta vs. S&P 500 | N/A |
| Revenue | $31.5 M |
| Net Profit Margin | -396.22% |
| Return on Equity | -164.73% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
